334: Ciryl Gane vs Josh Hokit
Slight lean to Yes: the bout is still scheduled and Gane’s health looks intact, which supports the market favorite. The evidence is fresh but mostly confirms the existing price, so I only move slightly above 66%.
Analysis
Nov. 8 reports still list Gane vs. Hokit as the UFC 334 main event. That keeps the market on track for a normal resolution and removes the main near-term cancellation risk.
Gane’s Nov. 6 interview reported no serious injuries, while the broader coverage still treats him as the deserved favorite. Hokit’s undefeated run is real, but it mostly supports his upset case rather than overturning the market favorite.
Arguments
For
- Recent reports still list the title fight as active.
- Gane’s health update showed no serious injuries.
Against
- Hokit is undefeated and has four UFC wins.
- Heavyweight bouts can swing quickly with one mistake.
Key drivers
- Fight is still scheduled and active as of Nov. 8.
- Gane’s reported health looks intact entering fight week.
Risk factors
- Late camp injury or withdrawal before Nov. 14.
- Hokit’s undefeated run could translate into a live upset threat.
Scenarios
Best case
If weigh-ins and final bout checks stay clean this week, Yes rises to about 72%.
Most likely
Most likely the fight happens as scheduled and Gane wins, with Yes around 68%.
Worst case
If Gane withdraws or is ruled unable to compete before Nov. 14, Yes falls to about 5%.
Outcomes
| Outcome | AI | MKT |
|---|---|---|
| Ciryl Gane | 68% | 66% |
| Josh Hokit | 32% | 35% |
More from this day
- economyPolymarket7mo
Swiss National Bank Decision in June?
AI2%MKT17%Edge-15HypedSlight lean to No: the SNB’s policy rate is already 0.00%, and the latest October CPI rose to 1.5% year over year, which makes a 50+ bp cut by June 2027 look very unlikely.
- politicsPolymarket16d
Pete Hegseth out as Secretary of Defense by...?
AI31%MKT19%Edge+12UndervaluedLeaning Yes: the market is probably a bit too low given the Nov. 9 impeachment push and the possibility Trump acts on the private replacement chatter. The main reason is that Hegseth faces real near-term pressure, even though he still has Trump’s public backing.
- pop culturePolymarket7mo
Grammys 2027: Album of the Year Winner
AI52%MKT42%Edge+10UndervaluedLeaning Yes: Olivia Rodrigo looks like an early frontrunner, with strong commercial numbers and fresh industry chatter pointing to a serious Album of the Year run. The most important near-term test is the November 16, 2026 nomination list, where this album is widely expected to appear.